Skip to main content

Neurodevelopmental Disorders

1
Pipeline Programs
7
Companies
8
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

IAMA Therapeutics
IAMA TherapeuticsItaly - Genoa
1 program
1
IAMA-6Phase 11 trial
Active Trials
NCT06300398Completed72Est. Nov 2024
ETS
ETSMO - Rolla
2 programs
Early interventionN/A1 trial
Shared book reading interventionN/A1 trial
Active Trials
NCT06512649Unknown48Est. May 2026
NCT06852989Active Not Recruiting53Est. Aug 2025
Young BioPharma
Young BioPharmaMA - Lowell
2 programs
Focused Acceptance and Commitment TherapyN/A1 trial
Focused Acceptance and Commitment TherapyN/A1 trial
Active Trials
NCT05584059Recruiting150Est. Dec 2025
NCT05803252Completed104Est. Feb 2026
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
DanceN/A1 trial
Active Trials
NCT04762290Completed35Est. Aug 2024
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Family networks programN/A1 trial
Active Trials
NCT02792894Completed540Est. Apr 2018
Eppendorf
EppendorfGermany - Hamburg
1 program
Longitudinal Study of Neurogenetic DisordersN/A1 trial
Active Trials
NCT03492060Recruiting1,000Est. Dec 2030

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
IAMA TherapeuticsIAMA-6
ETSShared book reading intervention
ETSEarly intervention
Young BioPharmaFocused Acceptance and Commitment Therapy
Young BioPharmaFocused Acceptance and Commitment Therapy
Angeles TherapeuticsDance
EppendorfLongitudinal Study of Neurogenetic Disorders
Human BioSciencesFamily networks program

Clinical Trials (8)

Total enrollment: 2,002 patients across 8 trials

NCT06300398IAMA TherapeuticsIAMA-6

IAMA-6 Oral Dose Study in Healthy Adults

Start: Jan 2024Est. completion: Nov 202472 patients
Phase 1Completed
NCT06852989ETSShared book reading intervention

Shared Interactive Book Reading in Preschool Children With Neurodevelopmental Disorders: Effects on Language Development and Reading Habits

Start: Feb 2025Est. completion: Aug 202553 patients
N/AActive Not Recruiting
NCT06512649ETSEarly intervention

Early Recognition and Intervention in Siblings at High-risk for Neurodevelopmental Disorder

Start: May 2023Est. completion: May 202648 patients
N/AUnknown
NCT05803252Young BioPharmaFocused Acceptance and Commitment Therapy

Videoconferencing-based Focused Acceptance and Commitment Therapy for Parents of SHCN Children

Start: Mar 2023Est. completion: Feb 2026104 patients
N/ACompleted
NCT05584059Young BioPharmaFocused Acceptance and Commitment Therapy

Pai.ACT Programme for Parents of Children With Special Healthcare Needs - Phase I

Start: Dec 2022Est. completion: Dec 2025150 patients
N/ARecruiting
NCT04762290Angeles TherapeuticsDance

Dance for Children With Autism

Start: Jan 2021Est. completion: Aug 202435 patients
N/ACompleted
NCT03492060EppendorfLongitudinal Study of Neurogenetic Disorders

Longitudinal Study of Neurogenetic Disorders

Start: Jun 2018Est. completion: Dec 20301,000 patients
N/ARecruiting
NCT02792894Human BioSciencesFamily networks program

Family Networks (FaNs) for Children With Developmental Disorders and Delays

Start: Apr 2016Est. completion: Apr 2018540 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 2,002 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.